First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience

Acta Oncologica

Volumn 51, Issue 1, 2012, Pages 97-100

  Olsen, Ingrid Holst ^a,b   Langer, Seppo W ^a   Jepsen, Ida ^a   Assens, Maria ^a   Federspiel, Birgitte ^a   Hasselby, Jane Preuss ^a   Hansen, Carsten Palnæs ^a   Kjær, Andreas ^a,b   Knigge, Ulrich ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CD56 ANTIGEN; ETOPOSIDE; METOCLOPRAMIDE; OCTREOTIDE; ONDANSETRON; PREDNISOLONE; VINCRISTINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG UPTAKE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NEUROENDOCRINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VINCRISTINE;

EID: 83455221060     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.582881     Document Type: Article

References (16)

1. Moertel CG., Kvols LK., O'Connell MJ., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
2. Mitry E., Baudin E., Ducreux M., Sabourin JC., Rufi e P., Aparicio T., et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
3. Oberg K., Astrup L., Eriksson B., Falkmer SE., Falkmer UG., Gustafsen J., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol 2004;43:617-25. (Pubitemid 39563934)
4. Janson ET., Sorbye H., Welin S., Federspiel B., Gronbaek H., Hellman P., et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol 2010;49:740-56.
5. Johnson LA., Lavin P., Moertel CG., Weiland L., Dayal Y., Doos WG., et al. Carcinoids: The association of histologic growth pattern and survival. Cancer 1983;51:882-9. (Pubitemid 13143167)
6. Rindi G., Bordi C., Rappel S., La RS., Stolte M., Solcia E. Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis., pathology., and behavior. World J Surg 1996;20:168-72. (Pubitemid 26069482)
7. Hainsworth JD., Johnson DH., Greco FA. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity. Ann Intern Med 1988;109:364-71.
8. Pelley RJ., Bukowski RM. Recent advances in diagnosis and therapy of neuroendocrine tumors of the gastrointestinal tract. Curr Opin Oncol 1997;9:68-74. (Pubitemid 27142555)
9. Moertel CG., Johnson CM., McKusick MA., Martin JK., Jr., Nagorney DM., Kvols LK., et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302-9. (Pubitemid 24050027)
10. Nilsson O., Van CE., Delle FG., Yao JC., Pavel ME., McNicol AM., et al. Poorly differentiated carcinomas of the foregut (gastric., duodenal and pancreatic). Neuroendocrinology 2006;84:212-5. (Pubitemid 46361055)
11. Ahlman H., Nilsson O., McNicol AM., Ruszniewski P., Niederle B., Ricke J., et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology 2008;87:40-6. (Pubitemid 350308293)
12. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12(Suppl 2):S111-4. (Pubitemid 33069698)
13. Yao JC., Hassan M., Phan A., Dagohoy C., Leary C., Mares JE., et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72.
14. National Comprehensive Cancer Network [Internet]. Fort Washington: NCCN; 2009. Clinical practice guidelines in oncology: Neuroendocrine tumors v.2.2009. Available from: http://www.nccn.org/professionals/physician-gls/PDF/ neuroendocrine.pdf.
15. B inderup T., Knigge U., Loft A., Federspiel B., Kjaer A. 18F-fl uorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-85.
16. Langer SW., Sorensen M. Treatment of small cell lung cancer. In: Hansen HH., editor. London: Informa; 2009.